NCT02040064View on ClinicalTrials.gov

Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Gefitinib

Oral tablet

DRUG

Tremelimumab

IV

Trial Locations (1)

94805

Gustave Roussy, Villejuif

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

NCT02040064 - Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients | Biotech Hunter | Biotech Hunter